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Abstract
Emerging evidence has shown that both prostatic basal and luminal cells are able to initiate 
oncogenic transformation. However, despite the diversity of tumor initiating cells, most prostate 
cancer cells express the androgen receptor (AR) and depend on androgens for their growth and 
expansion, implicating an essential role of androgen signaling in prostate tumorigenesis. Prostatic 
basal cells express p63 and are able to differentiate into luminal, neuroendocrine, and basal cells. 
Here, we directly assessed the essential role of androgen signaling in prostatic p63-expressing cell 
initiated oncogenic transformation and tumor formation. Using novel and relevant mouse models, 
we demonstrated that, with stabilized β-catenin expression, prostatic p63-expressing cells possess 
the ability to initiate oncogenic transformation and, in the presence of androgens, they further 
transdifferentiate into luminal-like tumor cells and develop adenocarcinomas. Castration prior to 
activating stabilized β-catenin sensitizes p63-expressing cells and increases their sensitivity to 
androgens, resulting in aggressive and fast growing tumor phenotypes. These findings are 
consistent with what have been observed in human prostate cancers, demonstrating an essential 
role for androgen signaling in prostate cancer initiation and progression. This study also provides 
fresh insight into developing new therapeutic strategies for better treating prostate cancer patients.
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INTRODUCTION
Prostate cancer is the most common non-cutaneous malignancy in men, contributing to 
27,500 deaths annually in the US 1. Androgen signaling, mediated through the androgen 
receptor (AR) and its ligands, testosterone and 5α-dihydrotestosterone (DHT) is essential 
for prostate cancer initiation and progression 2–4. Three cell populations in prostatic 
epithelium have been well defined, which include luminal, basal, and neuroendocrine cells. 
Both prostatic luminal and basal cells can be efficient targets for initiating oncogenic 
transformation 5–8. Early transplantation experiments showed that prostatic basal cells but 
not luminal cells were able to efficiently induce prostate tumor initiation 9, 10. However, 
recent studies using genetically engineered mouse models indicated that prostatic luminal 
cells are more sensitive to be targeted for prostate cancer initiation in comparison to basal 
cells 5–7. Intriguingly, despite the diversity of tumor-initiating cells in the prostate, almost all 
tumor cells developed from the above mouse models express the AR and depend on 
androgens for their growth and expansion 5–7. This is very similar to what has been observed 
in human primary prostate cancer, suggesting a decisive role of the androgen-signaling 
pathway in prostate cancer initiation and development.
Emerging evidence has shown an important role of the Wnt signaling pathways in prostate 
development and tumorigenesis 11, 12. Wnt responsive cells appear to possess stem/
progenitor cell properties in the mouse prostate 13. Abnormal expression of Wnt ligands, 
receptors, and effectors has been identified in prostate tumor and surrounding cells, 
suggesting paracrine regulatory mechanisms in prostate tumorigenesis 14, 15. Castration can 
elevate Wnt signaling and promote cell survival in the mouse prostate 16. The interaction 
between Wnt and androgen signaling pathways have been observed in prostate cancer cells 
17–19
. Co-expression of the AR and stabilized β-catenin in mouse prostatic luminal cells has 
been shown to accelerate tumor development and enhance tumor invasion and progression 
20
.
Prostatic basal cells express Ck5, Ck14, and p63, and contain prostatic stem/progenitor cell 
properties 21. Activation of oncogenic signaling in mouse Ck5 or Ck14 expressing cells 
induces transformation, and initiates tumor formation 5–7. The recent lineage tracing study 
identified several subpopulations of prostatic basal cells according to their different 
expression patterns of p63, Ck5 and Ck14 proteins 22. It appears that the majority of 
prostatic basal cells express p63, and those basal cells that express p63 but not Ck5 and 
Ck14 are more potent to differentiate into other prostatic epithelial lineages than other types 
of basal cells 22. Since p63 is a homologue of the p53 tumor suppressor 23, 24, it is unclear 
whether prostatic p63-expressing cells have the potential for initiating oncogenic 
transformation. In this study, we address these important questions using a diverse group of 
novel and relevant mouse models. We observed that prostatic p63 expressing cells possess 
the ability to initiate oncogenic transformation and, in the presence of androgens, these cells 
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are able to further transdifferentiate into luminal-like tumor cells and develop to 
adenocarcinomas. In addition, we also found that castration can sensitize prostatic p63-
expressing cells to androgens. With stabilized β-catenin expression, these androgen 
hypersensitive cells can develop into aggressive and fast growing tumors. These results 
illustrate a novel molecular mechanism by which androgen signaling in prostatic basal cells 
initiates tumor development and progression, providing fresh insight into our current 
knowledge to develop new therapeutic strategies for the treatment of advanced prostate 
cancer.
RESULTS
Conditional expression of stabilized β-catenin in prostatic p63-expressing cells at 
embryonic stages induces cell proliferation and abnormal cell foci formation.
Although it has been shown that prostatic p63 expressing cells possess stem/progenitor cell 
properties, their cellular potential to be targeted for oncogenic transformation still remains 
unclear. The expression of p63 was observed exclusively in cells localized in urogenital 
sinus epithelium (UGE) starting at or before embryonic day 13.5, E13.5 (Supplemental Fig. 
1A1–3’) 25, 26. To directly assess the ability of embryonic p63-expressing cells in initiating 
oncogenic transformation, we generated RosamTmG/+:p63CreERT2/+ and 
RosamTmG/+:Ctnnb1(ex3)fl/+:p63CreERT2/+ mice (Fig. 1A), in which the expression of mGFP, 
alone or with a stabilized form of β-catenin can be simultaneously induced in p63-
expressing cells through tamoxifen (TM) induction 27. To evaluate the cellular identity of 
p63-expressing cells, we administered TM at E13.5 to the above mice and then analyzed 
them at E18.5 (Fig. 1B). Using triple IF approaches, we detected the co-expression of p63 
and mGFP with E-cadherin, CK8, Ck5, AR, or Ki67 in UGE areas of 
RosamTmG/+:p63CreERT2/+ embryos (Supplemental Figure 1C-G). Our results demonstrates 
that prostatic p63-expressing cells are of epithelial origin and multipotent and possess 
proliferative characteristics. Intriguingly, we observed scattered cell clusters in the UGS 
areas of RosamTmG/+:Ctnnb1(ex3)fl/+:p63CreERT2/+ embryos (arrows, Fig. 1C1-E1). The 
expression of stabilized β-catenin was detected in the cytoplasm and nucleus of cells within 
those cell foci, which directly links the expression of stabilized β-catenin to the formation of 
cell foci. Co-expression of stabilized β-catenin with mGFP, p63, and E-cadherin also 
appeared in the cell clusters (Arrowheads Fig. 1C4-E4), demonstrating the origin of those 
proliferative cell clusters deriving from p63-expressing epithelial cells. We also observed co-
staining of stabilized β-catenin with Ck8 but no or very weak Ck5 in the cell clusters 
(arrowheads, Fig. 1F1-F2, and Supplemental Fig. 2A1–4 and 2B1–4). Using triple IF assays, 
we further confirmed the co-expression of mGFP and stabilized β-catenin with p63 and Ck8 
but not Ck5 in those cell foci (arrowheads, Fig. 1G5-I5). These data suggest that p63+Ck8+ 
and Ck5- cells may be a more proliferative cell population within the β-catenin-induced cell 
population. We also observed that co-expression of AR or Ki67 with stabilized β-catenin in 
the above cell clusters (arrowheads, Fig. 1F3–4, Supplemental Fig. 2C1–4 and 2D1–4). The 
expression of Ck8 and AR but not Ck5 within these cell foci suggest that stabilized β-
catenin can induce abnormal cell proliferation and luminal-like cell cluster formation in 
embryonic UGS tissues.
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Expression of stabilized β-catenin induces cell proliferation and initiates oncogenic 
transformation in prostatic prepubescent p63 expressing cells.
Next, we assessed the potential of prostatic prepubescent p63 expressing cells in oncogenic 
transformation. We injected TM in RosamTmG/+:Ctnnb1(ex3)fl/+:p63CreERT2/+ mice at 
postnatal day 14, P14 (Fig. 2A). The expression of mGFP appeared in prostate epithelium 
across different lobes at P21 (Fig. 2B-B’). Histological analyses reveal intraepithelial cluster 
lesions in four prostatic lobes (Fig. 2C1–3), which are mainly located in the basal side of 
prostate glands and display nuclear hyperchromasia (Fig. 2C1’−3’). IHC analyses showed 
that the atypical cells within those cell clusters express GFP, p63, and stabilized β-catenin in 
adjacent tissue sections (pink arrows, Fig. 2D1–3’). The co-expression of mGFP and β-
catenin, or mGFP and p63 was further detected in the atypical cell clusters on the adjacent 
tissue sections using co-IF approaches (arrowheads, Supplemental Fig. 3A1–3A2”). 
Interestingly, co-expression of AR or Ki67 with stabilized β-catenin was also observed in 
some atypical cells (Supplemental Fig. 3B1–3B2”), suggesting a regulatory role of 
androgen-signaling in prepubescent p63-expressing cell mediated oncogenic transformation. 
Co-IF analyses further showed that these prepubescent atypical cells were immunoreactive 
to Ck5, slightly to Ck14, but not to Ck8 antibody (Arrowheads, Fig. 2E1–3’), demonstrating 
the basal cell origin of these atypical cell clusters.
Since activating stabilized β-catenin causes severe skin lesions and mortality in 4 to 6-week-
old mice 28, we implanted prostate tissues isolated from the above 
RosamTmG/+:Ctnnb1(ex3)fl/+:p63CreERT2/+ mice under the renal capsule of NOD/SCID mice 
to further assess the fate of the clustered p63-expressing cells, (Fig. 2A). The grafts were 
collected 8 weeks post the implantation and appeared much larger in comparison to the sizes 
prior to the implantation. Most of cells within grafted tissues appeared mGFP positive (Fig. 
2F and F’), suggesting their origin of p63-expressing cells. Based on guidelines 
recommended by The Mouse Models of Human Cancers Consortium Prostate Pathology 
Committee in 2013 29, we observed typical pathological changes resembling mouse high-
grade PINs and multi-focal intracystic adenocarcinomas in the grafted tissues derived from 
four different prostatic lobes (Fig. 2G1–3’). Specifically, atypical intraductal proliferation of 
glandular cells with cribriform and partly solid patterns appears pronounced in the lesions. 
Both atypical and tumor cells show marked intraductal expansion with loss of cell polarity in 
the lumens. Some of the cells display nuclear atypia and hyperchromasia, with prominent 
nuclear atypia and occasional mitotic activities. As shown above, development of HGPIN 
and intracystic adenocarcinomas from a scatter of atypical proliferative cell clusters (Fig. 
2C1–3) provides direct evidence that prostatic p63-expressing cells are able to initiate 
oncogenic transformation and promote tumor formation. Most atypical and tumor cells in 
the above lesions showed positive staining with mGFP, β-catenin, Ck8, or AR antibody (Fig. 
2H1, 2, 5, and 6). However, only very few p63 or Ck5 positive cells appeared in grafted 
samples (Fig. 2H3–4). Co-expression of mGFP and stabilized β-catenin appears in most 
cells within the grafted tissues (Supplemental Fig. 3D1–3) while only a few scattered cells 
co-express mGFP with p63 (Supplemental Fig. 3E1–3, Supplemental Table 2) or Ck5 (Fig. 
2I2, and Supplemental Fig. 3H1–3). However, co-expression of both AR and Ck8, prostatic 
luminal cell markers, was observed in most atypical and tumor cells (Fig. 2I1 and 2I3, and 
Supplemental Fig. 3F1–3 and 3I1–3). Increased mGFP+Ki67+ cells also appeared in the 
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grafted tissues (Supplemental Fig. 3G1–3). These data indicate that prepubescent p63-
expressing cells with activating stabilized β-catenin expression are able to be transformed 
oncogenically, transdifferentiated, and form PIN and tumor lesions. Selective expansion of 
Ck8 and AR positive cells in the grafted tissues further suggests an essential role of 
androgen signaling for the transdifferentiation and growth of transformed p63-expressing 
cells.
Androgen deprivation sensitizes p63-expressing cells and enhances stabilized β-catenin 
induced prostate tumorigenesis.
We next further assessed the effect of androgens on prostatic p63-expressing cell initiated 
oncogenic transformation. A group of RosamTmG/+:Ctnnb1(ex3)fl/+:p63CreERT2/+ mice (n=4) 
were administered TM at ages of 8 weeks and analyzed at ages of 16 weeks (Experiment 1, 
Fig. 3A). We observed only intraepithelial cluster lesions derived from the basal layer in all 
of four prostatic lobes (Fig. 3B1–3’) but did not detect any other pathological abnormalities. 
Most atypical cells within clusters appear mGFP positive, suggesting their origin of p63 
expressing cells (arrowheads, Fig. 3C1–3). Co-IF analyses showed that the majority of cells 
within clusters co-express stabilized β-catenin with p63, AR, or Ck8, but only few with Ck5 
(Fig. 3D1-D4“, Supplemental Table 3). In contrast, another group of 
RosamTmG/+:Ctnnb1(ex3)fl/+:p63CreERT2/+ mice (n=6) were first castrated, then administered 
TM and supplemented androgens, and analyzed at age of 16 weeks (Experiment 2, Fig. 3A). 
Intriguingly, histologic analyses revealed pathologic lesions resembling mouse high-grade 
PIN and intracystic adenocarcinoma in all of four different prostatic lobes, featured typical 
intraductal proliferation of clusters and tufts with polygonal shapes and hyperchromatic 
nuclei, protruding into lumens (Fig. 3E1’−3’). Based on the guidelines recommended by The 
Mouse Models of Human Cancers Consortium Prostate Pathology Committee, these mice 
exhibited more aggressive lesions than the ones presented in Experiment 1 29 (Fig. 3E1–3’ 
versus 3B1–3’). Positive staining of GFP appeared in those proliferative cell clusters, 
indicating they originate from p63-expressing cells (Fig. 3F1–3). All of the atypical or tumor 
cells expressed stabilized β-catenin (Fig. 3G1). Co-IF analyses showed that the majority of 
atypical cells co-express stabilized β-catenin with Ck8 or AR (Fig. 3G3”-G4”, Supplemental 
Table 3). In contrast, only few cells showed co-expression of stabilized β-catenin with p63 
or Ck5 (Fig. 3G1”-G2”, Supplemental Table 3). These results demonstrate that castration 
can sensitize p63-expressing cells and enhance their abilities for proliferation and forming 
aggressive and fast growing tumor phenotypes upon activating stabilized β-catenin 
expression.
To further assess the androgen dependency of the above castration sensitized cells, we 
implanted prostate tissues isolated from RosamTmG/+:Ctnnb1(ex3)fl/+:p63CreERT2/+ mice 
(Experiment 2, Fig. 3A) under the renal capsule of either intact or castrated NOD/SCID 
mice (Figure 4A). The grafted tissues were analyzed at 12 weeks after transplantation. We 
observed regressed prostate glands with scattered residues of PIN lesions in implanted 
tissues isolated from castrated mice (Fig. 4B1–3’), demonstrating the requirement of 
androgens for the above cells. Analyses of cells within the above regressed glands showed 
weak staining of β-catenin, Ck8, and AR (Fig. 4C3, 4, and 6), and no staining for mGFP, 
p63, and Ck5 (Fig. 4C1, 2, and 5). In contrast, the grafted tissues from four different lobes of 
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intact mice showed fast growing and aggressive tumor lesions that feature multiple sheets of 
invasive carcinoma with marked nuclear atypia, pleomorphism, and frequent mitotic 
activities (Fig. 4D1–3’). These tumor cells showed positive staining of mGFP, β-catenin, 
Ck8, and AR, but no or very weak staining of p63 or Ck5 on adjacent sections (Fig. 4E1–6). 
Co-IF analyses showed that most tumor cells co-expressed stabilized β-catenin with Ck8 and 
AR (Supplemental Fig. 4C-C” and 4D-D”), but not p63 and Ck5 (Supplemental Fig. 4A-A” 
and 4B-B”). These data confirm an essential role of androgens in promoting the growth of 
castration-sensitized p63-expressing cells. Since most tumor cells were AR and Ck8 
positive, it further indicates the importance of androgens in transdifferentiating and 
expanding prostatic luminal-type of tumor cells from those castration-sensitized p63-
expressing cells.
Determining the effect of abnormal activation of β-catenin in inducing prostatic 
oncogenesis in tissue recombinants.
We then performed the tissue recombination assays to directly assess the oncogenic effect of 
p63-expressing cells upon stabilization of β-catenin. Both 
RosamTmG/+:Ctnnb1(ex3)fl/+:p63CreERT2/+ and RosamTmG/+:p63CreERT2/+ mice were castrated 
at age of 8 weeks, injected with TM at 12 weeks, and sacrificed at 20 weeks (Fig. 5A). 
Single cell suspensions prepared from prostate tissues of the above mice were transplanted 
with embryonic UGSM cells isolated from wild type mice under the renal capsule of either 
castrated or intact NOD/SCID mice. Mice were sacrificed and grafts were analyzed twelve 
weeks post implantation. In intact mice, grafts derived from prostate tissues of 
RosamTmG/+:p63CreERT2/+ mice appeared small and whitish, but, in contrast, ones from 
RosamTmG/+:Ctnnb1(ex3)fl/+:p63CreERT2/+ mice were large, yellowish, and containing blood 
vessels on the surface. Histologically, tubular epithelial structures with prostatic-like ducts 
appeared in samples of graft tissues from RosamTmG/+:p63CreERT2/+ controls (Fig. 5B1–2). 
Pathological lesions resembling typical high-grade PIN and multi-focal intracystic 
adenocarcinomas revealed in graft samples implanted with prostatic epithelial cells of 
RosamTmG/+:Ctnnb1(ex3)fl/+:p63CreERT2/+ mice (arrows, Fig. 5C1–2). Most tumor cells 
showed positive staining with GFP, β-catenin, Ck8, E-cadherin, and AR antibodies (Fig. 
5D1, 2, 5–7), only few cells stained with p63 and Ck5 antibodies (Fig. 5D3–4, Supplemental 
Table 5). There was no staining with synaptophysin (Fig. 5D8). Co-IF analyses showed co-
expression of GFP with β-catenin, Ck8, and AR in the majority of tumor cells, confirming 
prostatic luminal cell properties (Fig. 5E1–4. H1–4, and I1–4). However, only a few of cells 
showed co-staining of GFP with p63 or CK5 (Fig. 5F1–4 and G1–4). In addition, a 
significant portion of tumor cells showed positive staining of Ki67 (Fig. 5J1–4). In contrast, 
grafts derived from prostate tissues of RosamTmG/+:Ctnnb1(ex3)fl/+:p63CreERT2/+ or 
RosamTmG/+;p63CreERT2/+ appeared small and underdeveloped in castrated mice. 
Histologically, grafted tissues from RosamTmG/+:Ctnnb1(ex3)fl/+;p63CreERT2/+ mice failed to 
develop normal epithelium and only showed tissues mainly composed of prostatic stromal 
cells (Supplemental Fig. 5). These data suggest that the growth of prostate epithelium is 
solely dependent on androgens. Taken together, the above data further demonstrate the 
transformative ability of castration-sensitized p63-expressing cells in developing HGPIN 
and prostatic tumors and the requirement of androgens in castration-sensitized p63-
expressing cell initiated tumor formation.
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Androgen signaling plays a promotional role in p63-expressing cell mediated oncogenic 
transformation and tumor formation.
Androgen signaling is mainly regulated through the AR 2, 3. To directly evaluate the role of 
the AR in p63-expressing cells, we generated Ctnnb1(ex3)fl/+;R26hARL/+:p63CreERT2/+ mice, 
in which both the human AR and stabilized β-catenin transgenes are co-expressed in p63-
expressing cells (Fig. 6A) 30. As designed in Figure 6B, we performed a series of 
experiments to directly test the effect of AR on stabilized β-catenin mediated oncogenic 
transformation in prostatic p63-expressing cell using 
Ctnnb1(ex3)fl/+:R26hARL/+:p63CreERT2/+ mice and Ctnnb1(ex3)fl/+:p63CreERT2/+ controls. 
Typical proliferative cell clusters and PIN lesions appeared in four prostatic lobes of 
Ctnnb1(ex3)fl/+or Ctnnb1(ex3)fl/+:R26hARL/+:p63CreERT2/+ mice (Fig. 6C1–3, and 6E1–3), 
respectively. Pathological analyses revealed much worse and more aggressive lesions in the 
prostate of Ctnnb1(ex3)fl/+:R26hARL/+:p63CreERT2/+ compound mice than of 
Ctnnb1(ex3)fl/+;p63CreERT2/+ controls based on the guidelines recommended by The Mouse 
Models of Human Cancers Consortium Prostate Pathology Committee 29. Specifically, the 
lesions feature nuclear atypia and hyperchromasia and protrude or fill in lumens (Fig. 6E1–
3). Positive staining of β-catenin and Ck8 appeared in prostate tissues of the both genotype 
mice but the expression of human AR transgene was only observed in tissues of 
Ctnnb1(ex3)fl/+:R26hARL/+:p63CreERT2/+ compound mice (Fig. 6C4–6 and 6E4–6). To 
evaluate the fate of the above atypical cells, we transplanted the above prostate tissues 
isolated from both genotype mice under the renal capsules in the intact NOD/SCID mice 
(Fig. 6B). At 6 weeks after the transplantation, we analyzed the above mice and observed the 
formation of prostatic invasive adenocarcinomas in the grafts of prostatic tissues from 
Ctnnb1(ex3)fl/+:R26hARL/+:p63CreERT2/+ mice (Fig. 6F1–3). In contrast, only PIN lesions 
were observed in the samples derived from the prostates of Ctnnb1(ex3)fl/+:p63CreERT2/+ mice 
(Fig. 6D1–3). Again, only grafted tissues from Ctnnb1(ex3)fl/+:R26hARL/+:p63CreERT2/+ 
mice showed transgenic AR expression (Fig. 6F5) and an overall increase in androgen 
receptor expression (Supplemental Figure 6E). Using co-IF approaches, we assessed the co-
expression of Ki67 and stabilized β-catenin in the above tissues samples (Supplemental Fig. 
6A-A” and 6B-B”). Ki67 immunostaining was quantified by counting a total of 1000 β-
catenin expressing cells from five fields in each sample. Representative data from three 
individual experiments were shown that the epithelial proliferative index increased from 50 
in grafted samples of Ctnnb1(ex3)fl/+:p63CreERT2/+ mice to 150 in ones of 
Ctnnb1(ex3)fl/+:R26hARL/+:p63CreERT2/+ mice (Supplemental Fig. 6C), suggesting a 
promoting role of human AR transgene expression in the growth of prostatic β-catenin 
expressing cells. To investigate the molecular basis underlying transgenic AR and stabilized 
β-catenin expression in promoting prostate tumor cell growth, we performed real-time 
quantitative RT-PCR (qPCR) to assess the expression of Wnt/β-catenin downstream targets 
in RNA samples isolated from grafted tissues of both Ctnnb1(ex3)fl/+;p63CreERT2/+ and 
Ctnnb1(ex3)fl/+:R26hARL/+:p63CreERT2/+ mice. We observed a significant increase in 
expression of Lef1, c-Myc, Axin2, CD44, and Bex1 in tissues of 
Ctnnb1(ex3)fl/+;R26hARL/+:p63CreERT2/+ mice as compared to Ctnnb1(ex3)fl/+:p63CreERT2/+ 
mice (Supplemental Fig. 6D). Taken together, these results suggest that the expression of 
human AR transgene can enhance stabilized β-catenin mediated tumor growth and 
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progression, which may be through increasing the expression of β-catenin downstream 
target genes.
DISCUSSION
Emerging evidence has shown that both prostatic luminal and basal epithelial cells can be 
targeted for prostate cancer initiation 5–7. Both mouse Ck5 and Ck14 expressing cells are 
able to induce oncogenic transformation and initiate tumor formation 5–7. However, most 
prostate cancers developed in those mouse models contain prostatic luminal cell properties 
and are androgen dependent 5–7. Here, we used a variety of relevant mouse models and in 
vivo systems to directly address the significance of androgen signaling in oncogenic 
transformation and tumor development initiated from prostatic p63-expressing cells. We 
demonstrate that activating Wnt oncogenic signaling by expressing stabilized β-catenin in 
prostatic p63-expressing cells is able to induce cell proliferation and the formation of 
atypical cell clusters in different prostatic lobes at embryonic, prepubescent, and adult 
stages. Intriguingly, despite the androgen insensitive nature of prostatic p63-expressing cells, 
androgens are still essential for these cells to grow and develop to androgen-dependent, 
luminal cell type prostate tumors. These findings are consistent with what have been 
observed in human prostate cancers, in which the majority of tumor cells are androgen-
sensitive and possess luminal cell properties, providing new insight into the molecular 
mechanisms for prostate cancer initiation and progression.
Lineage tracing studies showed that prostatic p63-expressing cells are multipotent and able 
to develop to both basal and luminal cells 31, 32. Interestingly, the expression of p63 or Ck8, 
the basal or luminal cell markers, respectively, appears mutually exclusive during the course 
of prostate development and maturation in the adult prostate 32, 33. In this study, we 
observed that although the expression of stabilized β-catenin in prostatic p63-expressing 
cells induced oncogenic transformation, these cells needed to further transdifferentiate into 
prostatic luminal cells and then grow and expand in the presence of androgens. Using both 
IHC and co-IF approaches, we confirmed that most tumor cells express both Ck8 and AR, 
the cellular markers for prostatic luminal cells. In this study, we also observed that there was 
no or very limited growth of p63-expressing atypical cell clusters in castrated SCID host in 
comparison to intact counterparts. In addition, we also observed a significant regression in 
re-grafted prostate tumor samples isolated from intact hosts into castrated hosts. These 
above results demonstrate an indispensable role of androgens in prostatic basal cell initiated 
prostate cancer, which are also consistent with the similar observation in the conditional 
deletion of Pten tumor suppressor in prostatic Ck14 positive cells 6. Our data also implicate 
that the androgen-enriched microenvironment in the prostate selectively promotes the 
transdifferentiation of prostatic p63-expressing cells to androgen sensitive cells with 
prostatic luminal cell properties. The above observations are also similar to what happens in 
human prostate cancer, in which the majority of primary cancer cells possesses luminal cell 
properties and are ligand-dependent although they can further develop to androgen-
independent statues after androgen deprivation therapy (ADT). Interestingly, we did not 
observe the direct expansion of transformed p63-expressing cells in the prostate of 
Ctnnb1(ex3)fl/+:p63CreERT2/+ mice. Instead, our data depicts expansion of Ck8+ and AR+ 
luminal-like cells arising from the p63-expressing basal cells. Although the molecular 
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mechanisms underlying the inability of oncogenic transformed basal cells in developing into 
AR negative and androgen independent tumors in the mouse prostate are unclear currently, it 
may imply a repressive role of androgens in the growth of non-luminal prostatic cells in the 
prostate of the above mice. Therefore, further investigation using the above mouse models 
will provide fresh insight into developing more effective treatments for prostate cancer and 
prevent CRPC development.
As detailed in this study, we observed a much more aggressive prostate tumor phenotype in 
Ctnnb1(ex3)fl/+:p63CreERT2/+ mice that were castrated prior to TM administration in 
comparison to their counterparts that received TM directly (Fig. 3). These data suggest that 
castration can sensitize p63-expressing cells and enhance their abilities in oncogenic 
transformation, and androgen dependent cell growth and expansion. Our observations also 
provide a new insight into the mechanism underlying prostate cancer progression and 
castration resistant prostate cancer (CRPC) development. Although ADT is an effective 
treatment for prostate cancer, it eventually fails in nearly all cases of prostate cancer, and 
consequently patients develop CRPC, which is far more aggressive than the primary disease. 
Many mechanisms underlying prostate cancer progression and CRPC development have 
been elucidated. Specifically, it has been suggested that ADT may sensitize prostate cancer 
cells making them hypersensitive to androgens. These hypersensitive tumor cells can then 
grow and expand using alternative sources of androgens to develop and progress to more 
aggressive tumor phenotypes. Intra-tumoral synthesis of androgens has been detected in 
many patients with advanced diseases, providing direct evidence supporting the above 
hypothesis for disease progression 34. Therefore, better and combined therapeutic strategies 
should be considered to overcome the shortcomings of the current ADT in order to eliminate 
and reduce the androgen-hypersensitive tumor cells.
Multiple lines of evidence indicate abnormally activating Wnt/β-catenin signaling pathways 
can promote cell proliferation and induce oncogenic transformation 35. Expression of 
stabilized β-catenin in prostatic luminal cells results in hyperplasia and prostatic 
intraepithelial neoplasia (PIN) 36, 37. In addition to its oncogenic effect, stabilized β-catenin 
can also change cellular differentiation fate, which further results in either preventing 
prostate maturation or inducing transdifferentiation into squamous epithelium in the mouse 
prostate 36–38. As detailed in this study, we showed that the expression of stabilized β-
catenin in prostatic p63-expressing cells induce the formation of proliferative cell cluster, 
hyperplasia, and PIN formation at different stages of prostate development and maturation. 
In the presence of androgens, these transformed p63-expressing atypical cells further 
transdifferentiate to prostatic luminal cells and progress to lesions of high grade PIN and 
prostatic adenocarcinoma. These observations imply an essential role for androgen signaling 
in enhancing prostate tumor initiation and progression. It has been shown that an enrichment 
of AR and Wnt signaling pathways occurs in early-onset prostate cancer, but not in elderly-
onset prostate cancer 39, highlighting a clinical significance for a collaborative role of 
androgen and Wnt signaling pathways. To further validate the critical role of the AR in 
prostate tumorigenesis, we generated Ctnnb1(ex3)fl/+:R26hARL/+:p63CreERT2/+ mice in this 
study. We observed more aggressive PIN and adenocarcinoma lesions in 
Ctnnb1(ex3)fl/+:R26hARL/+:p63CreERT2/+compound mice than in Ctnnb1(ex3)fl/+:p63CreERT2/+ 
counterparts. A significant increase in the number of Ki67 positive cells was observed in 
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prostate tumor tissues of Ctnnb1(ex3)fl/+:R26hARL/+:p63CreERT2/+ in comparison to ones of 
Ctnnb1(ex3)fl/+:p63CreERT2/+. We searched for the molecular targets that are responsible for 
PIN and prostatic adenocarcinoma development in the above mouse models, and observed 
higher expression of Lef1, c-Myc, Axin2, Cd44, and Bex1 in the prostatic tissues of 
Ctnnb1(ex3)fl/+;R26hARL/+:p63CreERT2/+ compared to those from 
Ctnnb1(ex3)fl/+:p63CreERT2/+ mice. A protein-protein interaction between AR and β-catenin 
has been identified in prostate cancer cells 40–42. As we observed in the above experiments, 
the AR can enhance β-catenin-mediated transcription to result in prostate cancer 
aggressiveness and progression through the interaction. Further investigating the interaction 
between androgen and Wnt signaling pathways during course of prostate cancer initiation 
and progression may provide fresh insight in designing more effective therapeutic strategies 
for the treatment of advance prostate cancer patients.
MATERIALS AND METHODS
Mouse mating and genotyping.
P63CreERT2 was generated as described previously 22. RosamTmG (Jackson Laboratories; 
stock 7676) mice 43 were provided by Dr. Liqun Luo. Ctnnb1(ex3)fl mice were obtained from 
Dr. Makoto M. Taketo 27. R26hARL/+ mice were generated as described previously 30. All 
animal experiments performed in this study were approved by the Institutional Animal Care 
and Use Committee at Beckman Research Institute/City of Hope.
RosamTmG/mTmG and p63CreERT2/+ mice were crossed to generate RosamTmG/+ p63CreERT2/+ 
mice, which were then used to generate both RosamTmG/+ p63CreERT2/+ and RosamTmG/+ 
Ctnnb1(Ex3)fl/+ p63CreERT2/+ mice. We then bred p63CreERT2/+ and Ctnnb1(Ex3)fl/fl mice to 
generate Ctnnb1(Ex3)fl/+ p63CreERT2/+ mice. We further crossed p63CreERT2/+ Ctnnb1(Ex3)fl/fl 
and R26hARL/+ mice to generate both Ctnnb1(Ex3)fl/+ p63CreERT/+2 and R26hARL/+ 
Ctnnb1(Ex3)fl/+ p63CreERT/+2 mice. Genomic DNA samples isolated from mouse tail tips or 
embryo yolk sacs were used for genotyping with appropriate primers (see Supplemental 
Table 6) as described previously 44, 45.
Mouse procedures.
Castration of adult male mice was performed as described previously 46. For androgen 
supplement, testosterone pellets (12.5 mg, Innovative Research of America) were placed in 
mice subcutaneously. For tamoxifen induction, adult mice received a single intraperitoneal 
injection of 80μg/g body weight tamoxifen (Sigma), prepubescent mice (injected at P14) 
received a total dose of 1mg of tamoxifen, and pregnant mothers received a single 
intraperitoneal injection totaling 80μg/g body weight.
In vivo prostate regeneration assay.
Prostatic tissues were collected from different ages of mice and dissected into AP, DLP, and 
VP. Half of each prostatic lobe was implanted under the renal capsule of SCID mice and the 
rest of the tissues were prepared for histological analyses. The SCID mice were sacrificed 
and the graft tissues were collected and used for regrafting and histological analyses. For 
regeneration assays, either prostatic tissues or recombinants were prepared and implanted 
He et al. Page 10
Oncogene. Author manuscript; available in PMC 2019 June 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
under the renal capsule of SCID mice. For tissue recombination assays, mouse urogenital 
sinus mesenchyme (UGSM) cells collected and cultured as reported previously 47 were 
combined with approximately 1×105 of mGFP positive prostate epithelial cells collected 
from cell sorting, and then implanted under the renal capsule of 8-week-old castrated or 
intact SCID mice as described previously 13, 20.
Histology and immunostaining.
Serial sections were prepared from prostatic tissues for hematoxylin-eosin (H&E) staining or 
immunohistochemistry (IHC) 13, 20. For immunofluorescence (IF) staining and detection of 
mTmG signals, mouse tissues were fixed in 4% PFA at 4°C overnight, cryoprotected in 30% 
sucrose at 4°C overnight, and embedded in OCT (Tissue-Tek). Five micron sections were 
obtained for mTmG and IF analyses 13. Both primary and second antibodies used in this 
study were listed in Supplemental Table 8.
RNA Isolation and Reverse Transcription (RT)-Quantitative PCR (qPCR) Assays.
Mouse tissues were homogenized in RNA-Bee (TEL-TEST, Inc., Friendswood, TX) and 
total RNA was isolated as recommended by the manufacturer. Reverse transcription was 
carried out as described previously 20. For quantitative PCR, cDNA samples were mixed 
with SYBR GreenER qPCR Super Mix Universal (11762, Invitrogen) and appropriate 
primers (Supplemental Table 7) for amplifying specific gene expression in the MX 3005P 
thermocycler (Stratagene). Relative mRNA levels were calculated 20. Reactions were done 
in triplicate, and the values were normalized to GAPDH (glyceraldehyde3-phosphate 
dehydrogenase) expression levels.
Microscope image acquisition.
Images of H&E and IHC were acquired on an Axio Lab. A1 microscope using 10x and 40x 
Zeiss A-Plan objectives with a Canon EOS 1000D camera and using Axiovision software 
(Carl Zeiss). Images of immunofluorescence staining and mTmG signals and were acquired 
on an Nikon ECLIPSE E800 epi-fluorescence microscope using 10x and 40x Nikon Plan 
Fluor objectives with an QImaging RETIGA EXi camera and using QCapture software 
(QImaging). Statistical analyses were performed using 2-tailed Student’s t test or 2-way 
ANOVA.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Conditional expression of stabilized β-catenin in p63-expressing cells at embryonic 
stage induces atypical cluster formation.
A. Schematic illustration of transgenic alleles and tamoxifen-inducible recombination events 
present in RosamTmG/+, Ctnnb1fl(Ex3)/+, and p63CreERT2/+ mice. The expression of either 
membrane-targeted tdTomato (mT) or membrane-targeted EGFP (mG) is regulated by the 
pCA promoter, consisting of a chicken β-actin core promoter with a CMV enhancer, through 
Cre/LoxP mediated recombination. B. Schematic representation depicting experimental 
timeline for labeling and analyzing UGS tissues during embryonic stage. Pregnant females 
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received a single dose of tamoxifen on E13.5 and UGS tissues were isolated at E18.5. C-E. 
Immunofluorescent staining of UGS tissues from RosamTmG/+ Ctnnb1fl(Ex3)/+ p63CreERT2/+ 
embryos using antibodies against β-catenin (red), (C) GFP, (D) p63, (E) E-cad (green). F. 
Immunofluorescent staining of UGS tissues from RosamTmG/+ Ctnnb1fl(Ex3)/+ p63CreERT2/+ 
embryos using antibodies against β-catenin (red) and (F1) Ck8, (F2) Ck5, (F3) AR or (F4) 
Ki67 (green) G-I. Triple immunofluorescent staining of GFP (green), beta-catenin (blue) 
with (G) p63, (H) Ck8 or (I) Ck5 (red). Arrows (C-I) denote proliferative intraepithelial cell 
clusters expressing stabilized β-catenin (n=3).
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Figure 2. Conditional expression of stabilized β-catenin in prostatic prepubescent p63 expressing 
cells induces cell proliferation and oncogenic transformation.
A. Schematic representation of experimental design. RosamTmG/+ Ctnnb1fl(Ex3)/+ 
p63CreERT2/+ mice (n=6) received a single tamoxifen injection on P14. Prostate tissues were 
isolated and dissected into individual lobes one week later (P21). Half of each lobe was 
implanted under the kidney capsule of SCID mice, while the other half was preserved for 
histological and immunofluorescent analyses. Kidney grafts. B and F. mTmG fluorescence 
of (B-B’) P21 prostate tissues prior to implantation under the kidney capsule and (F-F’) 
graft tissues eight weeks after implantation in the kidney. C. H&E stained sections of 
different prostatic lobes, (C1-C1’) anterior prostate (AP), (C2-C2’) dorsolateral prostate (D/
LP), and (C3-C3’) ventral prostate (VP) from RosamTmG/+ Ctnnb1fl(Ex3)/+ p63CreERT2/+ 
mice at P21. Immunohistochemical staining of sequential sections of the same tissues with 
(D1-D1’) p63, (D2-D2’) GFP or (D3-D3’) β-catenin antibodies (brown). Sections are 
counterstained with hematoxylin (blue). E. Immunofluorescent staining of stabilized β-
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catenin (green) with (E1) Ck5, (E2) Ck14 or (E3) Ck8 (red). G. H&E stained sections of 
graft tissues derived from different prostatic lobes. H. IHC staining of sequential sections of 
graft tissues with (H1) GFP, (H2) β-catenin, (H3) p63, (H4) Ck5, (H5) Ck8, or (H6) AR 
antibodies (brown). Sections are counterstained with hematoxylin (blue). I. 
Immunofluorescent images of graft tissues generated from RosamTmG/+ Ctnnb1fl(Ex3)/+ 
p63CreERT2/+ prostates stained with antibodies against GFP (green) and (I1) AR, (I2) Ck5, 
or (I3) Ck8 (red).
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Figure 3. Androgen deprivation sensitizes p63-expressing cells and enhances prostate 
tumorigenesis induced by stabilized β-catenin upon replacement of androgen.
A. Schematic depicting experimental timeline for castration, TM injection, androgen 
replacement and analysis. Experiment 1: RosamTmG/+ Ctnnb1fl(Ex3)/+ p63CreERT2/+ mice 
were injected with tamoxifen at age of eight weeks and prostate tissues were isolated at age 
of sixteen weeks (n=4). Experiment 2: RosamTmG/+ Ctnnb1fl(Ex3)/+ p63CreERT2/+ mice were 
castrated at age of eight weeks, injected with tamoxifen at age of twelve weeks followed by 
androgen replacement at age of 13.5 weeks. Prostate tissues were isolated and dissected into 
individual lobes at age of 17.5 weeks (n=6). B. H&E stained sections of different prostatic 
lobes, (B1) AP, (B2) D/LP and (B3) VP, isolated from mice described in Experiment 1. C. 
Fluorescent images of mT (red) and mG (green) expression in the different prostate lobes, 
(C1) AP, (C2) D/LP and (C3) VP of mice described in Experiment 1. D. Immunofluorescent 
staining of prostate tissues from RosamTmG/+ Ctnnb1fl(Ex3)/+ p63CreERT2/+ using antibodies 
against β-catenin (green) and (D1-D1”) p63, (D2-D2”) Ck5, (D3-D3”) Ck8 or (D4-D4”) 
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AR (red). E. H&E stained sections of different prostatic lobes, (E1) AP, (E2) D/LP and (E3) 
VP, isolated from RosamTmG/+ Ctnnb1fl(Ex3)/+ p63CreERT2/+ described in Experiment 2. F. 
Fluorescent images of mT (red) and mG (green) expression in the different prostate lobes, 
(F1) AP, (F2) D/LP and (F3) VP of mice described in Experiment 2. G. Immunofluorescent 
staining of prostate tissues from RosamTmG/+ Ctnnb1fl(Ex3)/+ p63CreERT2/+ using antibodies 
against β-catenin (green) and (G1-G1”) p63, (G2-G2”) Ck5, (G3-G3”) Ck8 or (G4-G4”) 
AR (red). Arrows (B-G) denote proliferative intraepithelial cell clusters expressing 
stabilized β-catenin.
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Figure 4. Tumorigenesis caused by stabilization of stabilized β-catenin in sensitized p63-
expressing cells is androgen dependent.
A. Schematic depicting experimental timeline for kidney capsule transplantation in both 
castrated and intact SCID mice. RosamTmG/+ Ctnnb1fl(Ex3)/+ p63CreERT2/+ were castrated at 
eight weeks of age. Four weeks later, the mice were injected with a single dose of tamoxifen 
and were supplemented with androgen. At 16 weeks of age, these mice prostate tissues were 
isolated and implanted under the kidney capsule of either intact or castrated SCID mice. 
Tissue grafts were dissected twelve weeks later (n=4). B. H&E stained sections of graft 
tissues derived from different prostatic lobes, (B1) AP, (B2) D/LP and (B3) VP, in castrated 
SCID mice. C. IHC staining of sequential sections of graft tissues harvested from castrated 
SCID mice with (C1) GFP, (C2) p63, (C3) β-catenin, (C4) Ck8, (C5) Ck5 or (C6) AR 
(brown). Sections are counterstained with hematoxylin (blue). D. H&E stained sections of 
graft tissues derived from different prostatic lobes, (D1) AP, (D2) D/LP and (D3) VP, 
harvested from intact SICD mice. E. IHC staining of sequential sections of graft tissues 
from intact SCID mice with (E1) GFP, (E2) p63, (E3) β-catenin, (E4) Ck8, (E5) Ck5 or 
(E6) AR (brown). Sections are counterstained with hematoxylin (blue).
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Figure 5. Stabilization of β-catenin in sensitized p63-expressing cells resulted in oncogenesis in 
tissue recombinants.
A. Schematic depicting preparation of recombinants and timeline for kidney capsule 
transplantation. RosamTmG/+ p63CreERT2/+ or RosamTmG/+ Ctnnb1fl(Ex3)/+ p63CreERT2/+ mice 
were castrated at the age of eight weeks, injected with TM at the age of twelve weeks, and 
sacrificed eight weeks later. Prostate tissues were isolated and cells were sorted for GFP 
expression using FACS. GFP-positive cells were implanted under the kidney capsule of 
intact SCID mice along with wild-type urogenital sinus mesenchyme tissue. Tissue grafts 
were isolated twelve weeks later (n=3). B-C. H&E stained sections of tissue graft 
recombinants made of UGSM and GFP-positive epithelial cells from the prostates of either 
(B) RosamTmG/+ p63CreERT2/+ or (C) RosamTmG/+ Ctnnb1fl(Ex3)/+ p63CreERT2/+ mice. D. 
IHC staining of sequential sections of tissues grafts from RosamTmG/+ Ctnnb1fl(Ex3)/+ 
p63CreERT2/+ mice using antibodies against (D1) GFP, (D2) β-catenin, (D3) p63, (D4) Ck5, 
(D5) Ck8, (D6) E-cad, (D7) AR or (D8) Synaptophysin (brown). Sections are counterstained 
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with hematoxylin (blue). E-J. Immunofluorescent staining of tissue recombinants generated 
from RosamTmG/+ Ctnnb1fl(Ex3)/+ p63CreERT2/+ mice using antibodies against GFP (green) 
and (E) β-catenin, (F) p63, (G) Ck5, (H) Ck8, (I) AR, or (J) Ki67 (red).
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Figure 6. Androgen signaling plays a promotional role in oncogenic transformation induced by 
stabilized β-catenin in p63-expressing cells.
A. Illustration of transgenic alleles present in R26hARL/+Ctnnb1fl(Ex3)/+p63CreERT2/+ mice. 
Expression of the R26hARL/+transgene is driven by a modified CAG promoter and is 
activated by Cre-mediated removal of a Lox-Stop-Lox neomycin cassette. B. Schematic of 
experimental timeline. R26hARL/+Ctnnb1fl(Ex3)/+p63CreERT2/+ and 
Ctnnb1fl(Ex3)/+p63CreERT2/+ mice were castrated at eight weeks of age and injected with 
tamoxifen at age of 12 weeks. Then the mice were supplemented with androgen pellets. At 
the age of 16 weeks, mice were sacrificed, the prostates were harvested and implanted under 
the kidney capsule of SCID mice. Tissue grafts were isolated from SCID mice six weeks 
later (n=3). C. Histological analyses of prostate tissues isolated from 
Ctnnb1fl(Ex3)/+p63CreERT2/+ mice prior to kidney grafting. H&E stained sections of the (C1) 
AP, (C2) D/LP and (C3) VP. IHC staining of sequential section of prostatic tissues with 
antibodies for (C4) β-catenin, (C5) h-AR or (C6) Ck8 (brown). D. Histological analyses of 
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prostate tissues isolated from R26hARL/+Ctnnb1fl(Ex3)/+p63CreERT2 mice prior to kidney 
grafting. H&E stained sections of the (D1) AP, (D2) D/LP or (D3) VP. IHC staining of 
sequential sections with (D4) β-catenin, (D5) h-AR or (D6) Ck8 antibodies (brown). E. 
Histological analyses of tissue grafts derived from Ctnnb1fl(Ex3)/+p63CreERT2 mice. H&E 
stained sections of graft tissues derived from the (E1) AP, (E2) D/LP or (E3) VP. IHC 
staining of sequential sections with (E4) β-catenin, (E5) h-AR or (E6) Ck8 antibodies 
(brown). F. Histological analyses of tissue grafts derived from 
R26hARL/+Ctnnb1fl(Ex3)/+p63CreERT2 mice. H&E stained sections of grafts derived from the 
(F1) AP, (F2) D/LP or (F3) VP. IHC staining of sequential sections with (F4) β-catenin, 
(F5) h-AR or (F6) Ck8 antibodies (brown).
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